Evidence map›Paper›PMID 42093158›Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2026

Estrogen-mediated NF-κB blockade enables breast cancer sensitivity to oncolytic VSV virotherapy.

Mélissa Viens, Karen Geoffroy, Elline Meuriot, Alexandra Buccilli, Victor Mullins-Dansereau, Marie-Lou Myre, Stamatios Paradisis, Angelina Bardoul, Emma Mary Kalin, Bruna Araripe Saraiva and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Mélissa ViensCancer Axis and Institut du Cancer de Montréal, Centre Hospitalier de l'Université de Montréal (CHUM) Research Center, Montreal, QC H2X 0A9, Canada; Immunopathology Axis, CHUM Research Center, Montreal, QC H2X 0A9, Canada; Department of Microbiology, Infectious Diseases, and Immunology, University of Montreal, Montreal, QC H3C 3J7, Canada.
Karen GeoffroyCancer Axis and Institut du Cancer de Montréal, Centre Hospitalier de l'Université de Montréal (CHUM) Research Center, Montreal, QC H2X 0A9, Canada; Immunopathology Axis, CHUM Research Center, Montreal, QC H2X 0A9, Canada; Department of Microbiology, Infectious Diseases, and Immunology, University of Montreal, Montreal, QC H3C 3J7, Canada.
Elline MeuriotCancer Axis and Institut du Cancer de Montréal, Centre Hospitalier de l'Université de Montréal (CHUM) Research Center, Montreal, QC H2X 0A9, Canada; Immunopathology Axis, CHUM Research Center, Montreal, QC H2X 0A9, Canada; Department of Microbiology, Infectious Diseases, and Immunology, University of Montreal, Montreal, QC H3C 3J7, Canada.
Alexandra BuccilliCancer Axis and Institut du Cancer de Montréal, Centre Hospitalier de l'Université de Montréal (CHUM) Research Center, Montreal, QC H2X 0A9, Canada; Immunopathology Axis, CHUM Research Center, Montreal, QC H2X 0A9, Canada; Department of Microbiology, Infectious Diseases, and Immunology, University of Montreal, Montreal, QC H3C 3J7, Canada.
Victor Mullins-DansereauCancer Axis and Institut du Cancer de Montréal, Centre Hospitalier de l'Université de Montréal (CHUM) Research Center, Montreal, QC H2X 0A9, Canada; Immunopathology Axis, CHUM Research Center, Montreal, QC H2X 0A9, Canada; Department of Microbiology, Infectious Diseases, and Immunology, University of Montreal, Montreal, QC H3C 3J7, Canada.
Marie-Lou MyreCancer Axis and Institut du Cancer de Montréal, Centre Hospitalier de l'Université de Montréal (CHUM) Research Center, Montreal, QC H2X 0A9, Canada; Immunopathology Axis, CHUM Research Center, Montreal, QC H2X 0A9, Canada; Department of Microbiology, Infectious Diseases, and Immunology, University of Montreal, Montreal, QC H3C 3J7, Canada.
Stamatios ParadisisCancer Axis and Institut du Cancer de Montréal, Centre Hospitalier de l'Université de Montréal (CHUM) Research Center, Montreal, QC H2X 0A9, Canada; Immunopathology Axis, CHUM Research Center, Montreal, QC H2X 0A9, Canada; Department of Microbiology, Infectious Diseases, and Immunology, University of Montreal, Montreal, QC H3C 3J7, Canada.
Angelina BardoulCancer Axis and Institut du Cancer de Montréal, Centre Hospitalier de l'Université de Montréal (CHUM) Research Center, Montreal, QC H2X 0A9, Canada; Department of Microbiology, Infectious Diseases, and Immunology, University of Montreal, Montreal, QC H3C 3J7, Canada.
Emma Mary KalinCancer Axis and Institut du Cancer de Montréal, Centre Hospitalier de l'Université de Montréal (CHUM) Research Center, Montreal, QC H2X 0A9, Canada; Immunopathology Axis, CHUM Research Center, Montreal, QC H2X 0A9, Canada; Department of Microbiology, Infectious Diseases, and Immunology, University of Montreal, Montreal, QC H3C 3J7, Canada.
Bruna Araripe SaraivaCancer Axis and Institut du Cancer de Montréal, Centre Hospitalier de l'Université de Montréal (CHUM) Research Center, Montreal, QC H2X 0A9, Canada; Immunopathology Axis, CHUM Research Center, Montreal, QC H2X 0A9, Canada; Department of Microbiology, Infectious Diseases, and Immunology, University of Montreal, Montreal, QC H3C 3J7, Canada.
Jeffrey ValenciaCancer Axis and Institut du Cancer de Montréal, Centre Hospitalier de l'Université de Montréal (CHUM) Research Center, Montreal, QC H2X 0A9, Canada; Immunopathology Axis, CHUM Research Center, Montreal, QC H2X 0A9, Canada; Department of Microbiology, Infectious Diseases, and Immunology, University of Montreal, Montreal, QC H3C 3J7, Canada.
Kim Leclerc DesaulniersCancer Axis and Institut du Cancer de Montréal, Centre Hospitalier de l'Université de Montréal (CHUM) Research Center, Montreal, QC H2X 0A9, Canada.
Huy-Dung HoangChildren's Hospital of Eastern Ontario Research Institute, Ottawa, ON K1H 8L1, Canada; Department of Biochemistry, Microbiology, and Immunology, University of Ottawa, Ottawa, ON K1N 6N5, Canada.
Saima HassanCancer Axis and Institut du Cancer de Montréal, Centre Hospitalier de l'Université de Montréal (CHUM) Research Center, Montreal, QC H2X 0A9, Canada; Immunopathology Axis, CHUM Research Center, Montreal, QC H2X 0A9, Canada.
John Cameron BellDepartment of Biochemistry, Microbiology, and Immunology, University of Ottawa, Ottawa, ON K1N 6N5, Canada; Cancer Research Program, Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada.
Barbara VanderhydenCancer Research Program, Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada; Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON K1N 6N5, Canada.
Tommy AlainChildren's Hospital of Eastern Ontario Research Institute, Ottawa, ON K1H 8L1, Canada; Department of Biochemistry, Microbiology, and Immunology, University of Ottawa, Ottawa, ON K1N 6N5, Canada.
Dominic Guy RoyCancer Axis and Institut du Cancer de Montréal, Centre Hospitalier de l'Université de Montréal (CHUM) Research Center, Montreal, QC H2X 0A9, Canada; Department of Microbiology, Infectious Diseases, and Immunology, University of Montreal, Montreal, QC H3C 3J7, Canada.
David Parker CookCancer Research Program, Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada; Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON K1N 6N5, Canada.
Marie-Claude Bourgeois-DaigneaultCancer Axis and Institut du Cancer de Montréal, Centre Hospitalier de l'Université de Montréal (CHUM) Research Center, Montreal, QC H2X 0A9, Canada; Immunopathology Axis, CHUM Research Center, Montreal, QC H2X 0A9, Canada; Department of Microbiology, Infectious Diseases, and Immunology, University of Montreal, Montreal, QC H3C 3J7, Canada. Electronic address: marie-claude.bourgeois-daigneault@umontreal.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Novel therapies are urgently needed for breast cancer. While our previous work investigating the use of oncolytic viruses against the disease demonstrated its promise, heterogeneous responses were observed. Interestingly, breast cancer is classified into subtypes based on the expression of hormone receptors. We noted that triple-negative breast cancers (TNBCs), which lack the expression of the estrogen (E2) receptor (ER) were resistant to the oncolytic vesicular stomatitis virus (oVSV), whereas ER

Indexed as

Breast NeoplasmsEstrogensNF-kappa BOncolytic VirotherapyOncolytic VirusesTriple Negative Breast NeoplasmsVesicular stomatitis Indiana virusAnimalsCell Line, TumorFemaleHumansReceptors, EstrogenVirus ReplicationEstrogensNF-kappa BReceptors, Estrogenbreast cancerestradiolestrogenNF-κBoncolytic virusvesicular stomatitis virus

Identifiers

PMID42093158
PMCPMC13464137

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.